JP2008527038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008527038A5 JP2008527038A5 JP2007552192A JP2007552192A JP2008527038A5 JP 2008527038 A5 JP2008527038 A5 JP 2008527038A5 JP 2007552192 A JP2007552192 A JP 2007552192A JP 2007552192 A JP2007552192 A JP 2007552192A JP 2008527038 A5 JP2008527038 A5 JP 2008527038A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 3-amino-2- (R, S) -fluoropropyl Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000394 mitotic effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000005275 alkylenearyl group Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 230000020347 spindle assembly Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000007755 survival signaling Effects 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001672 cytoproliferative effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000007275 lymphatic system cancer Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64493305P | 2005-01-19 | 2005-01-19 | |
| PCT/US2006/001364 WO2006078574A2 (en) | 2005-01-19 | 2006-01-13 | Mitotic kinesin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008527038A JP2008527038A (ja) | 2008-07-24 |
| JP2008527038A5 true JP2008527038A5 (https=) | 2009-03-05 |
| JP4545196B2 JP4545196B2 (ja) | 2010-09-15 |
Family
ID=36692758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552192A Expired - Fee Related JP4545196B2 (ja) | 2005-01-19 | 2006-01-13 | 有糸分裂キネシン阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080102068A1 (https=) |
| EP (1) | EP1856128A4 (https=) |
| JP (1) | JP4545196B2 (https=) |
| CN (1) | CN101107253A (https=) |
| AU (1) | AU2006206738A1 (https=) |
| CA (1) | CA2595127A1 (https=) |
| WO (1) | WO2006078574A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| US20130331294A1 (en) | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| NZ602089A (en) | 2010-02-17 | 2014-05-30 | Takeda Pharmaceutical | Heterocyclic compounds having cell division cycle 7 inhibitory activity |
| JP2013523867A (ja) * | 2010-04-15 | 2013-06-17 | ノバルティス アーゲー | Ｋｓｐ阻害剤としてのトリアゾール化合物 |
| EP2558452A2 (en) * | 2010-04-15 | 2013-02-20 | Novartis AG | Oxazole and thiazole compounds as ksp inhibitors |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| MA46228A (fr) * | 2016-09-14 | 2019-07-24 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
| CN109689663B (zh) | 2016-09-14 | 2023-04-14 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| AU2020409437A1 (en) * | 2019-12-18 | 2022-07-14 | Universite De Montreal | Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds |
| JP7554829B2 (ja) | 2019-12-19 | 2024-09-20 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換直鎖スピロ誘導体 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE327224T1 (de) * | 1999-10-27 | 2006-06-15 | Cytokinetics Inc | Chinazolinone benutzende verfahren und zusammenstellungen |
| AU2002364128B2 (en) * | 2001-12-06 | 2008-03-06 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| US7378411B2 (en) * | 2001-12-06 | 2008-05-27 | Merck & Co., Inc. | Substituted thienopyrimidinones as a mitotic kinesin inhibitor |
| US7262187B2 (en) * | 2001-12-06 | 2007-08-28 | Merck & Co., Inc. | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor |
| US20050107404A1 (en) * | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| CA2489562A1 (en) * | 2002-07-08 | 2004-01-15 | Merck & Co., Inc. | Mitotic kinesin binding site |
| WO2004064741A2 (en) * | 2003-01-17 | 2004-08-05 | Cytokinetics Inc. | Compounds, compositions, and methods |
| JP3947758B2 (ja) * | 2003-03-07 | 2007-07-25 | アストラゼネカ アクチボラグ | 新規縮合ヘテロサイクル及びその使用 |
-
2006
- 2006-01-13 EP EP06718441A patent/EP1856128A4/en not_active Withdrawn
- 2006-01-13 WO PCT/US2006/001364 patent/WO2006078574A2/en not_active Ceased
- 2006-01-13 JP JP2007552192A patent/JP4545196B2/ja not_active Expired - Fee Related
- 2006-01-13 CA CA002595127A patent/CA2595127A1/en not_active Abandoned
- 2006-01-13 US US11/795,440 patent/US20080102068A1/en not_active Abandoned
- 2006-01-13 AU AU2006206738A patent/AU2006206738A1/en not_active Abandoned
- 2006-01-13 CN CNA2006800025407A patent/CN101107253A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008527038A5 (https=) | ||
| Lang et al. | Nitrogen-containing heterocycles as anticancer agents: An overview | |
| JP5931982B2 (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP2009514881A5 (https=) | ||
| JP2009514880A5 (https=) | ||
| JP2009541223A5 (https=) | ||
| JP2007517071A5 (https=) | ||
| JP2018504418A5 (https=) | ||
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| JP2009516653A5 (https=) | ||
| JP2014034576A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| JP2008527039A5 (https=) | ||
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| RU2014150860A (ru) | Режим дозирования pi-3 киназы | |
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| JP2008527041A5 (https=) | ||
| JPWO2020163823A5 (https=) | ||
| US20060235006A1 (en) | Combinations, methods and compositions for treating cancer | |
| JP2013511526A5 (https=) | ||
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor |